Predictors of high‐quality cord blood units

Santos, Sandra Valéria; Barros, Sônia; Santos, Marisa; Marti, Luciana Cavalheiro; Ribeiro, Andreza Alice Feitosa; Kondo, Andrea Tiemi; Kutner, José Mauro

doi:10.1111/trf.13653

Cited by 13 publications

(31 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Maternal age at delivery has been analyzed in 28 of 71 articles . In most articles, no significant correlation was found with UCB volume, TNCs, CD34+ cells, or CFU (Fig.…”

Section: Highlighted Factorsmentioning

confidence: 99%

“…During a Cesarean, the newborn infant is usually positioned higher than the placenta, thus favoring the downflow of blood into the placental cord and consequently into the umbilical compartment. Moreover, the placenta is expelled manually and more rapidly than after vaginal delivery, which may reduce the possibility of blood clot formation . Hemodilution occuring during Cesarean delivery may also be a reason for the increased volume, whereas the TNC increase in vaginal delivery is related to the fetal stress response, which increases cytokine levels in the fetal circulatory system …”

Section: Highlighted Factorsmentioning

confidence: 99%

See 1 more Smart Citation

Associated factors of umbilical cord blood collection quality

et al. 2017

View full text Add to dashboard Cite

After 30 years of hematopoietic stem cell use for various indications, umbilical cord blood is considered as an established source of cells with marrow and postmobilization peripheral blood. The limited number of cells still remains a problematic element restricting their use, especially in adults who require to be grafted with a higher cell number. Improving the quality of harvested cord blood, at least in terms of volume and amount of cells, is essential to decrease the number of discarded units. In this review, we examine several variables related to parturient, pregnancy, labor, delivery, collection, the newborn, umbilical cord, and placenta. We aim to understand the biologic mechanisms that can impact cord blood quality. This knowledge will ultimately allow targeting donors, which could provide a rich graft and improve the efficiency of the collection.

show abstract

“…Maternal age at delivery has been analyzed in 28 of 71 articles . In most articles, no significant correlation was found with UCB volume, TNCs, CD34+ cells, or CFU (Fig.…”

Section: Highlighted Factorsmentioning

confidence: 99%

Section: Highlighted Factorsmentioning

confidence: 99%

Associated factors of umbilical cord blood collection quality

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In addition, several other factors in the perinatal period also exert a strong influence on UCB‐SCs. It has been shown that greater placental weight and umbilical cord length are associated with greater volumes of extracted UCB and a greater quantity of UCBCs, including hematopoietic stem cells, TNCs, and CFUs (Ballen et al, ; Page et al, ; Santos et al, ). Shorter gestation tends to result in more hematopoietic stem cells and a higher CFU count, but a lower volume of UCB and a lower TNC count (Manegoldbrauer et al, ).…”

Section: Sources Of Ucb‐scs In Preterm Infantsmentioning

confidence: 99%

Umbilical cord blood stem cell therapy in premature brain injury: Opportunities and challenges

Peng

Shi

et al. 2019

J of Neuroscience Research

View full text Add to dashboard Cite

Preterm birth and associated brain injury are the primary cause of cerebral palsy and developmental disabilities and are among the most serious global health issues that modern society faces. Current therapy for infants suffering from premature brain injury is still mainly supportive, and there are no effective treatments. Thus there is a pressing need for comparative and translational studies on how to reduce brain injury and to increase regeneration and brain repair in preterm infants. There is strong supporting evidence for the use of umbilical cord blood (UCB)‐derived stem cell therapy for treating preterm brain injury and neurological sequelae. UCB‐derived stem cell therapy is effective in many animal models and has been shown to be feasible in clinical trials. Most of these therapies are still experimental, however. In this review, we focus on recent advances on the efficacy of UCB‐derived stem cell therapy in preterm infants with brain injury, and discuss the potential mechanisms behind their therapeutic effects as well as application strategies for future preclinical and clinical trials.

show abstract

“…They can also be found in cord blood (CB) in a similar frequency to PB (2), but the small volume in CB units represents the difficulty in obtaining suitable numbers of NK cells needed for clinical use (3). Human NK cells are phenotypically described as CD3 − CD56 + cells within the lymphocyte population (4), and they are classified as a subset within the group 1 of innate lymphocyte cells, capable of producing IFN-γ, and exert cytotoxicity (5).…”

Section: Introductionmentioning

confidence: 99%

OP9 Feeder Cells Are Superior to M2-10B4 Cells for the Generation of Mature and Functional Natural Killer Cells from Umbilical Cord Hematopoietic Progenitors

Herrera¹,

Salcedo²,

Santos³

et al. 2017

Front. Immunol.

View full text Add to dashboard Cite

Adoptive natural killer (NK) cell therapy relies on the acquisition of large numbers of mature and functional NK cells. An option for future immunotherapy treatments is to use large amounts of NK cells derived and differentiated from umbilical cord blood (UCB) CD34+ hematopoietic stem cells (HSCs), mainly because UCB is one of the most accessible HSC sources. In our study, we compared the potential of two stromal cell lines, OP9 and M2-10B4, for in vitro generation of mature and functional CD56+ NK cells from UCB CD34+ HSC. We generated higher number of CD56+ NK cells in the presence of the OP9 cell line than when they were generated in the presence of M2-10B4 cells. Furthermore, higher frequency of CD56+ NK cells was achieved earlier when cultures were performed with the OP9 cells than with the M2-10B4 cells. Additionally, we studied in detail the maturation stages of CD56+ NK cells during the in vitro differentiation process. Our data show that by using both stromal cell lines, CD34+ HSC in vitro differentiated into the terminal stages 4–5 of maturation resembled the in vivo differentiation pattern of human NK cells. Higher frequencies of more mature NK cells were reached earlier by using OP9 cell line than M2-10B4 cells. Alternatively, we observed that our in vitro NK cells expressed similar levels of granzyme B and perforin, and there were no significant differences between cultures performed in the presence of OP9 cell line or M2-10B4 cell line. Likewise, degranulation and cytotoxic activity against K562 target cells were very similar in both culture conditions. The results presented here provide an optimal strategy to generate high numbers of mature and functional NK cells in vitro, and point toward the use of the OP9 stromal cell line to accelerate the culture procedure to obtain them. Furthermore, this method could establish the basis for the generation of mature NK cells ready for cancer immunotherapy.

show abstract

Predictors of high‐quality cord blood units

Abstract: This study provides elements for a model that allows an efficient selection of UCB donors, prioritizing candidates who have a better chance to lead to an optimized use of cord blood cells units.

Cited by 13 publications

References 27 publications

Associated factors of umbilical cord blood collection quality

Associated factors of umbilical cord blood collection quality

Umbilical cord blood stem cell therapy in premature brain injury: Opportunities and challenges

OP9 Feeder Cells Are Superior to M2-10B4 Cells for the Generation of Mature and Functional Natural Killer Cells from Umbilical Cord Hematopoietic Progenitors

Contact Info

Product

Resources

About